Sabre is set to sell its hospitality solutions business to alternative asset management firm TPG for $1.1 billion in cash. TPG will invest in Hospitality Solutions, which provides software and ...

Off-target toxicity has killed off one of Bolt Biotherapeutics’ lead programs. Rather than push BDC-2034 into the clinic, the immuno-oncology startup is winding down spending on the anti-tumor ...